Login
EANO

Corporate Symposia

Corporate Symposia

Corporate Symposium (CS01) | Servier

 

IDH Inhibition in Clinical Practice: Addressing Remaining Questions in Glioma

Friday, September 25 | 13:45 - 14:45 hrs | Sinopoli Hall

13:45 – 13:48

Welcome

Giuseppe Minniti – Co-Chair  
University of Sapienza, Italy

13:48 – 13:58

Unravelling the Complexity of Gliomagenesis

Luis Nicolas Gonzalez Castro - Speaker
Dana Farber Institute, Boston, USA

13:58 – 14:13

From IDH Biology to Clinical Outcomes: INDIGO in Daily Practice

Patrick Roth – Speaker
University Hospital of Zurich, Switzerland 

14:13 – 14:33

How to manage and follow-up challenging mIDH Glioma Patients? 

Anna Berghoff - Speaker
University Hospital of Vienna, Austria

14:33 – 14:45

Q&A and Take Home Messages 

Corporate Symposium (CS02) | Oxford Nanopore Technologies

 

 

Transforming Neuro-Oncology with Real Time Methylation and Molecular Profiling

 

Friday, September 25 | 13:45- 14:45 hrs | Petrassi Hall
 
13:45 – 13:55

Welcome/Opening

Ângela Serrano, Oxford Nanopore Technologies

13:55 – 14:15

Implementing Oxford Nanopore PromethION 2i for integrated molecular profiling of pediatric brain tumors

Dr. Elena Pasquinelli
Neuro-Oncology Unit, Meyer Children’s Hospital IRCCS, Florence, Italy

14:15 – 14:20

Q&A

Ângela Serrano, Oxford Nanopore Technologies

14:20 – 14:40

Establishing a real-time intra-operative CNS tumor classification pipeline using Nanopore sequencing 

 

Rahul Kumar, MD PdH
Mayo Clinic, Department of Neurologic Surgery, Rochester, MN, USA

14:40 – 14:45Q &A 
Ângela Serrano, Oxford Nanopore Technologies

 

Corporate Symposium (CS03) | Jazz Pharmaceuticals

The Evolving Landscape of Diffuse Gliomas: From Molecular Profiling to Emerging Treatment Strategies

 
Friday, September 25 | 13:45 - 14:45 hrs | Theatre Studio

13:45 – 13:50

Welcome/Opening

Prof. Susan Short
Univ. of Leeds, Leeds, West Yorkshire, England

13:50 – 14:05

Review current approaches to the diagnosis and molecular characterization of diffuse gliomas 

Dr. Mayen Briggs - Speaker
Neuropathologist at Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK


14:05 – 14:20

Evaluate the evolution to treatment strategies for H3 K27M-mutant diffuse gliomas

Giuseppe Lombardi, MD, PhD – Speaker
Veneto Institute of Oncology, Padua, Italy 

14:20 – 14:35

Assess recent clinical evidence and ongoing research efforts in diffuse gliomas 

Alessia Pellerino, MD, PhD - Speaker
University and City of Health and Science Hospital, Turin, Italy

14:35 – 14:45Q&A/Discussion

Corporate Symposium (CS04) | Servier

 

The Hidden Burden of Glioma Patients Revealed By Real World Data

 
Saturday, September 26 | 13:45 - 14:15 hrs | Theatre Studio

13:45 – 13:50

Introduction: Discussing Integration of Patient Choice

Roberta Ruda, Helen Bulbeck

13:50 – 14:00

The Impact of Glioma on Daily Life and the Household 

Jane Skjøth-Rasmussen  - Speaker


14:00 – 14:10

Amplifying Patient Voice in Registries Through Digital

Maria Vieito – Speaker
 

14:10 – 14:15

What the Data Doesn't Tell us: The Patient Advocacy 

Helen Bulbeck - Speaker


Corporate Symposium (CS05) | Merck Healthcare KGaA

 

CARE FOR RARE: Navigating treatment approaches in NF1-associated plexiform neurofibroma

 
Saturday, September 26 | 14:15 - 14:45 hrs | Petrassi Hall

14:15 – 14:20

Welcome and Introduction to NF1-PN

Angela Mastronuzzi – Chair

14:20 – 14:30

Case-based journey through the treatment algorithm: Evaluating our options; individualising our approach

Said Farschtschi - Speaker


14:30 – 14:40

Managing symptomatic, inoperable NF1-PN: What do the data tell us?

Timothy Gershon – Speaker
 

14:40 – 14:45

Practical Panel discussion & Q&A 

All


14:45

Closing 

Angela Mastronuzzi - Chair